FI7617U1 - Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste - Google Patents

Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste

Info

Publication number
FI7617U1
FI7617U1 FI20070036U FIU20070036U FI7617U1 FI 7617 U1 FI7617 U1 FI 7617U1 FI 20070036 U FI20070036 U FI 20070036U FI U20070036 U FIU20070036 U FI U20070036U FI 7617 U1 FI7617 U1 FI 7617U1
Authority
FI
Finland
Prior art keywords
active ingredient
pharmaceutical preparation
stabilized pharmaceutical
amorphous active
amorphous
Prior art date
Application number
FI20070036U
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Andrej Bastarda
Rok Grahek
Mateja Salobir
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI7617(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of FIU20070036U0 publication Critical patent/FIU20070036U0/fi
Application granted granted Critical
Publication of FI7617U1 publication Critical patent/FI7617U1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI20070036U 2002-10-11 2007-01-26 Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste FI7617U1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (fr) 2002-10-11 2003-10-10 Preparation pharmaceutique stabilisee renfermant une substance amorphe active

Publications (2)

Publication Number Publication Date
FIU20070036U0 FIU20070036U0 (fi) 2007-01-26
FI7617U1 true FI7617U1 (fi) 2007-09-28

Family

ID=32091984

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20070036U FI7617U1 (fi) 2002-10-11 2007-01-26 Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste

Country Status (21)

Country Link
US (2) US20040077708A1 (fr)
EP (1) EP1608362B1 (fr)
CN (1) CN100372529C (fr)
AR (1) AR041588A1 (fr)
AT (2) ATE354362T1 (fr)
AU (1) AU2003280361B2 (fr)
CY (1) CY1106608T1 (fr)
CZ (1) CZ17610U1 (fr)
DE (2) DE60312049T2 (fr)
DK (2) DK1608362T3 (fr)
ES (1) ES2285205T3 (fr)
FI (1) FI7617U1 (fr)
ME (1) ME00514B (fr)
PT (1) PT1608362E (fr)
RS (1) RS51819B (fr)
RU (1) RU2358727C2 (fr)
SI (2) SI21302A (fr)
SK (1) SK5233Y1 (fr)
TW (1) TWI320709B (fr)
UA (1) UA85544C2 (fr)
WO (1) WO2004032920A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
JP4739672B2 (ja) 2001-12-21 2011-08-03 ネクター セラピューティクス 湿気のバリアを有するカプセルパッケージ
PL1653930T3 (pl) * 2003-08-05 2008-06-30 Zentiva Ks Sposoby stabilizacji atorwastatyny
AU2004317570B2 (en) 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2582449A1 (fr) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Atorvastatine calcique amorphe
CA2589537A1 (fr) * 2004-12-02 2006-06-08 Stephen Craig Dyar Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr) * 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (fr) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (fr) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Emballage de dose d'unité
EP2522348B1 (fr) 2009-12-25 2016-05-25 Sawai Pharmaceutical Co., Ltd. Préparation enrobée contenant de l'atorvastatine
WO2013072770A2 (fr) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
EA201791737A1 (ru) * 2015-02-03 2018-03-30 КАДМОН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Стабильные составы триентина
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (fr) 2015-12-21 2017-06-28 Hexal AG Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (fr) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DK0783301T3 (da) * 1994-09-30 1999-08-02 Becton Dickinson Co Fremgangsmåde til udformning og pakning af iontoforetiske medikamentleveringsplastre og lignende med henblik på forøgelse a
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
ATE418979T2 (de) * 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
HRP20020950A2 (en) * 2000-06-09 2004-12-31 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Unité de distribution pour médicaments sensibles à l'oxygène

Also Published As

Publication number Publication date
ATE354362T1 (de) 2007-03-15
WO2004032920A1 (fr) 2004-04-22
CY1106608T1 (el) 2012-01-25
DK1608362T3 (da) 2007-05-14
CN1703215A (zh) 2005-11-30
EP1608362B1 (fr) 2007-02-21
DK200700025U1 (da) 2007-06-08
DE60312049T2 (de) 2007-10-04
CZ17610U1 (cs) 2007-06-18
AT10424U1 (de) 2009-03-15
RS51819B (sr) 2011-12-31
ES2285205T3 (es) 2007-11-16
AU2003280361A1 (en) 2004-05-04
DE20321455U1 (de) 2007-05-24
US20040077708A1 (en) 2004-04-22
CN100372529C (zh) 2008-03-05
DK200700025U4 (da) 2008-03-14
SI21302A (sl) 2004-04-30
UA85544C2 (ru) 2009-02-10
RU2358727C2 (ru) 2009-06-20
ME00514B (fr) 2011-10-10
RS20050273A (sr) 2007-06-04
SK50062007U1 (en) 2009-03-05
TWI320709B (en) 2010-02-21
TW200501947A (en) 2005-01-16
DE60312049D1 (de) 2007-04-05
US20090012150A1 (en) 2009-01-08
RU2005114485A (ru) 2006-01-27
SK5233Y1 (en) 2009-09-07
EP1608362A1 (fr) 2005-12-28
FIU20070036U0 (fi) 2007-01-26
AR041588A1 (es) 2005-05-26
AU2003280361B2 (en) 2009-02-26
SI1608362T1 (sl) 2007-12-31
PT1608362E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
FIU20070036U0 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
PT1501534E (pt) Formulacoes farmaceuticas
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
FI7568U1 (fi) Farmaseuttinen lantaanikarbonaattiformulaatio
EP1477403A4 (fr) Distributeur de medicament
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
NO20033384L (no) Farmasoytisk formulering
NO20033785L (no) Farmasöytisk formulering
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
NO20035627D0 (no) Farmasöytisk formulering
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
EP1399467A4 (fr) Promedicaments actives par peptide deformylase
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
EP1581196A4 (fr) Compositions de medicaments labiles acides
AU2003244259A1 (en) Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
EE200300045A (et) Kristalne ravimaine
IS7846A (is) Aðferð til að framleiða lyfjafræðilega virkt efnasamband og til að framleiða milliefni þess

Legal Events

Date Code Title Description
FGU Utility model registered

Ref document number: 7617

Country of ref document: FI

TCU Change of name of patent owner for a utility model

Owner name: LEK PHARMACEUTICALS D.D.

Free format text: LEK PHARMACEUTICALS D.D.

MAU Utility model expired